Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts Eye and Ear Infirmary
Study ID
NCT04752020
Phase
EARLY_PHASE1
Status
Completed

Conditions

  • Fuchs' Endothelial Dystrophy

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This will be a prospective assessment of whether adjuvant Netarsudil use in patients undergoing Descemetorhexis without endothelial keratoplasty improves time to corneal clearance and post-operative central endothelial cell counts. The anticipated enrollment is 25 patients.

Key Dates

Start date
Mar 28, 2021
Status verified
Mar 2024
Primary completion
Jun 28, 2023
Completion
Dec 30, 2023

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Netarsudil use
    Patients will receive Netarsudil eye drops to use 1 drop nightly in the operative eye after DWEK surgery until corneal clearance

Primary Outcome Measure

Change in central corneal pachymetry over time [ Time Frame: Measured at post-operative month one visit and then every 2 months for 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts Eye and Ear InfirmaryBostonMassachusetts02127-

Find similar trials in Boston, MA

By research site
Massachusetts Eye and Ear Infirmary· Boston, MA

Related Studies